A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib

Trial Profile

A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Apr 2018

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms RESORCE
  • Sponsors Bayer; Bayer HealthCare
  • Most Recent Events

    • 18 Apr 2018 Results focusing on biological interpretation of circulating miRNA biomarkers predicting regorafenib clinical benefit presented at the 109th Annual Meeting of the American Association for Cancer Research
    • 20 Jan 2018 Results of retrospective analysis assessing association between hand-foot skin reaction and overall survival presented at the 2018 Gastrointestinal Cancers Symposium
    • 17 Jan 2018 According to a Bayer media release, data will be present at the American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancer Symposium 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top